BPC-157 Dosage Chart

Overview of BPC-157 Dosing in Research Contexts

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. In preclinical studies, researchers have administered it across a wide range of doses depending on the target tissue, route of administration, and study duration. Unlike many compounds where a universal protocol exists, bpc157 dosing varies considerably based on whether the research goal involves musculoskeletal repair, gastrointestinal healing, or neurological support. Understanding the variables that influence dose selection is essential for interpreting published findings accurately.

Standard Dosage Ranges by Administration Route

The most commonly cited doses in animal and in-vitro research fall between 1 mcg/kg and 10 mcg/kg of body weight. When extrapolated to a 70 kg human equivalent using standard allometric scaling, this translates roughly to a range of 70 mcg to 700 mcg per administration. Most published protocols cluster around 200 mcg to 500 mcg per injection for subcutaneous or intramuscular use.

Subcutaneous Administration

Subcutaneous injection is the most frequently used route in research models studying systemic or soft-tissue applications. Doses in this range are typically 200 mcg to 400 mcg, administered once or twice daily. Injection sites are rotated to avoid localized tissue saturation, and the peptide is reconstituted in bacteriostatic water at concentrations that allow precise microdosing with an insulin syringe.

Intramuscular Administration

Intramuscular protocols appear in studies focused on muscle fiber repair and tendon-to-bone attachment recovery. The dose range mirrors subcutaneous protocols at 200 mcg to 500 mcg, but injection directly into or adjacent to the target tissue is sometimes used in localized injury models. This site-specific approach allows researchers to examine paracrine effects distinct from systemic circulation.

Oral Administration

Oral dosing of bpc157 is studied primarily in gastrointestinal research, where the peptide's stability in acidic environments makes ingestion a viable route. Research using oral gavage in rodents has used doses ranging from 10 mcg/kg to 100 mcg/kg. Some research groups use a dissolved oral solution rather than capsule form to standardize absorption timing.

Dosage Chart by Research Application

The following reference ranges summarize doses most commonly reported across peer-reviewed and preprint literature. These figures are for research orientation only and do not represent clinical recommendations.

• Tendon and ligament repair models: 200 mcg to 500 mcg subcutaneously, once daily for 2 to 4 weeks
• Gastrointestinal mucosal healing: 10 mcg/kg to 100 mcg/kg orally, administered over 7 to 14 days
• Muscle injury and regeneration: 250 mcg to 400 mcg intramuscularly, once daily near injury site
• Bone healing studies: 200 mcg to 300 mcg subcutaneously, twice daily for 4 weeks
• Neurological and CNS injury models: 1 mcg/kg to 5 mcg/kg systemically, with daily or alternate-day protocols

Dosing Frequency and Cycle Duration

Most preclinical studies run BPC-157 protocols for 10 to 30 days. Shorter windows of 7 to 14 days appear in acute injury models, while chronic or degenerative tissue studies extend dosing to 28 days or longer. Daily administration is the most common frequency, though some studies have used twice-daily dosing to maintain tighter plasma concentration windows. Research does not yet support the benefit of continuous long-cycle use beyond 30 days, and most protocols include an observation period after the dosing phase to assess durability of effect.

Cycle timing relative to the injury model also matters in the literature. Some studies administer the peptide immediately post-injury, while others introduce it 24 to 48 hours after the insult to isolate repair-phase effects from acute inflammation modulation. Researchers designing experiments should account for this variable when benchmarking against existing data.

Reconstitution and Concentration Considerations

BPC-157 is typically supplied as a lyophilized powder in vials of 2 mg to 5 mg. For subcutaneous use, common reconstitution targets a concentration of 500 mcg/mL to 1000 mcg/mL using bacteriostatic water, allowing precise dosing with a 0.5 mL or 1 mL insulin syringe. Vials should be stored at 4 degrees Celsius after reconstitution and used within 28 days. Exposure to repeated freeze-thaw cycles degrades peptide integrity and is avoided in rigorous research protocols.

Accurate pipetting and syringe calibration are critical given the small volumes involved. A 200 mcg dose from a 1000 mcg/mL solution requires drawing only 0.2 mL, meaning any measurement error has a proportionally large impact on the actual dose delivered. Research groups typically verify concentration via HPLC when precision is required.

Research Limitations and Interpretation Notes

The dosing data summarized here comes almost entirely from rodent models. Direct extrapolation to other species requires allometric conversion and should account for differences in metabolic rate, body surface area, and tissue pharmacokinetics. Human clinical data on bpc157 remains limited, and no regulatory body has approved it for therapeutic use. All dosing information on this page is intended strictly to support the interpretation of existing preclinical literature and to inform the design of new research protocols under appropriate oversight.